Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions

EP. 1: Use of the Anti-HER3 Antibody Seribantumab in Preclinical Models

ByD. Ross Camidge, MD, PhD,Alexander Spira, MD, PhD, FACP

August 20th 2021

Experts review a preclinical study of the anti-HER3 monoclonal antibody seribantumab, used in cell lines and mouse models of solid tumors.

EP. 2: Potential Translational Relevance of Preclinical Findings With Seribantumab

ByD. Ross Camidge, MD, PhD,Alexander Spira, MD, PhD, FACP

August 26th 2021

Thoracic oncologists discuss key takeaways and potential translational relevance of seribantumab based on a recent publication by Igor Odintsov, MD, and colleagues.

Anti-HER3 Antibodies May Inhibit Growth of Tumors Harboring NRG1 Fusions

EP. 1: Use of the Anti-HER3 Antibody Seribantumab in Preclinical Models

EP. 2: Potential Translational Relevance of Preclinical Findings With Seribantumab

Trending on CancerNetwork

Ficerafusp Alfa/Pembrolizumab Receives FDA BTD in Front-Line HNSCC

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer

ESMO 2025: Key Anticipated Updates in Breast and Lung Tumors

Safety Strategies for GPRC5D-Directed and T-Cell Engager Therapies

LAURA Trial, SINDAS Trial, NORTHSTAR Trial, and LONESTAR Trial